Tata Medical and Diagnostics, the healthcare unit of the Tata Group, is in the initial stage of discussion with US-based Moderna to partner and launch its vaccine against COVID-19 in India, the Economic Times reported on Monday.
The company may team up with India’s Council of Scientific and Industrial Research to carry out clinical trials of Moderna’s vaccine. Moderna received funds from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop the mRNA-1273 COVID-19 vaccine.
The vaccine has side effects similar to other COVID-19 vaccines like pain, swelling, redness at the site of vaccination, and tiredness and headache. The efficacy rate of the Moderna vaccine was 94.1% based on the clinical trial report published by the Centers for Disease Control and Prevention(CDCP).
The FDA earlier issued an Emergency Use Authorization for Moderna vaccine in the United States.
